急性冠脉综合征后的睡眠障碍

2018-06-11 沿若 医学论坛网心血管

巴尔的摩——一项观察性研究的结果显示,急性冠脉综合征(ACS)后一个月内连续出现睡眠障碍的患者患创伤后应激障碍(PTSD)的风险增加。


巴尔的摩——一项观察性研究的结果显示,急性冠脉综合征(ACS)后一个月内连续出现睡眠障碍的患者患创伤后应激障碍(PTSD)的风险增加。

来自纽约哥伦比亚大学的行为心血管健康中心的Ari Shechter博士表示:“这些发现表明,在ACS事件之后,瞄准解决睡眠障碍可能有助于预防PTSD等不良心理结果。”该研究结果发表在睡眠2018:第32届睡眠联合协会年会上。
 
急性冠脉综合征诱发的创伤后应激障碍相对常见,大约每8个病人中就有1个患有此病。睡眠障碍是创伤后应激障碍的一个特征,因此本研究旨在检测急性冠脉综合症事件后睡眠持续时间短及低质量睡眠和随后的创伤后应激障碍的发病之间的关系。
 
惊人的结果
 
研究人员分析了纳入的270名(平均年龄61岁;48%为女性)经历了急性护理和住院治疗患者的数据-(REACH)研究,这是一项正在进行的观察队列研究,以探测在评估了ACS后与长期精神疾病和医疗结果相关的因素。

ACS评估之后一个月,患者报告的睡眠时间和睡眠质量。使用精神障碍诊断标准与统计手册第五版(DSM-5) PTSD量表(PCL-5)对6个月内的创伤后应激障碍进行评估。

ACS一个月后,56%的患者反馈睡眠不足(<7小时/夜),30%的患者反馈睡眠质量差(相当/非常差)。
 
“令人吃惊的是,”Shechter说,“近60%的患者报告说,在他们的急性冠脉综合症发作后的一个月里睡眠时间很短;超过四分之一的患者报告说,在这段时间里,睡眠时间短并且质量差。这很重要,”他指出,“因为我们从其他研究中得知,短时间睡眠——尤其是短时间睡眠合并低质量睡眠——与不良的心血管疾病预后有关。”
 
超过十分之一(11%)患者出现创伤后应激障碍(PCL-5评分≥38分)。与未患PTSD组群相比,患有创伤后应激障碍的人的睡眠质量明显更短,质量也更差。
 
在ACS后的一个月里,睡眠时间短或睡眠质量差的患者在ACS后6个月内患PTSD的几率是睡眠充足和/或睡眠质量良好的患者的3倍以上。
 
“然而,从这项研究中,我们仍不能确切解释睡眠障碍与ACS诱导PTSD的机制,甚至真正的导向关系:到底是睡眠不好导致了创伤后应激障碍,还是有创伤后应激障碍体质的个体恶化了其睡眠。”Schechter说道。
 
睡眠不好会导致生理性压力,例如引起自主神经系统失调并增加交感神经系统的活性。睡眠时间短或低质量睡眠会使人感到焦虑或紧张,而这种心理和生理上的压力和觉醒机制的综合可能是睡眠障碍导致PTSD的一个原因。
 
而且,ACS事件后的糟糕睡眠会导致反复发生的心血管事件和死亡率升高。因此,总的来说,尽管还有更多的工作要做,但这些发现表明,预防和/或治疗睡眠不足应在冠脉事件后优先被考虑,以帮助增强心理和生理健康。
 
原始出处:

Cite this article: Disrupted Sleep After Cardiac Event May Increase PTSD Risk - Medscape - Jun 05, 2018.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1431238, encodeId=62db143123852, content=<a href='/topic/show?id=f9b9e9124a8' target=_blank style='color:#2F92EE;'>#综合征#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79124, encryptionId=f9b9e9124a8, topicName=综合征)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Wed Jun 13 11:12:00 CST 2018, time=2018-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=323741, encodeId=7856323e413a, content=学习一下谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzaiabIFicf63hKvVMjL6aJlx4yX4UcXmzX9DyibCRcicq0QtCRWMaQKh8MYjE1D3EKUBopgiaGWYuqbeR/0, createdBy=0c2b1999806, createdName=三生有幸9135, createdTime=Wed Jun 13 06:27:37 CST 2018, time=2018-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=323435, encodeId=274732343553, content=好文献学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b5a62240667, createdName=张新亮1853311252142e2fm, createdTime=Tue Jun 12 05:52:17 CST 2018, time=2018-06-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=323377, encodeId=b2f43233e73d, content=创伤应激?, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18741984753, createdName=smartxiuxiu, createdTime=Mon Jun 11 22:41:16 CST 2018, time=2018-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=323354, encodeId=7b4432335412, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/6r91EF8BMOLCD55MqUYf0ibGeibzcwCxaSD5XqTv5sRrxxzV9TpHfN8fDaNYCt8Jay98QLKHyzBpkr1f4v2EIcDQ/132, createdBy=c24466863, createdName=liuchuan1982, createdTime=Mon Jun 11 21:01:38 CST 2018, time=2018-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=323341, encodeId=83b7323341c9, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=82311653708, createdName=医者仁心5538, createdTime=Mon Jun 11 20:26:03 CST 2018, time=2018-06-11, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1431238, encodeId=62db143123852, content=<a href='/topic/show?id=f9b9e9124a8' target=_blank style='color:#2F92EE;'>#综合征#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79124, encryptionId=f9b9e9124a8, topicName=综合征)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Wed Jun 13 11:12:00 CST 2018, time=2018-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=323741, encodeId=7856323e413a, content=学习一下谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzaiabIFicf63hKvVMjL6aJlx4yX4UcXmzX9DyibCRcicq0QtCRWMaQKh8MYjE1D3EKUBopgiaGWYuqbeR/0, createdBy=0c2b1999806, createdName=三生有幸9135, createdTime=Wed Jun 13 06:27:37 CST 2018, time=2018-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=323435, encodeId=274732343553, content=好文献学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b5a62240667, createdName=张新亮1853311252142e2fm, createdTime=Tue Jun 12 05:52:17 CST 2018, time=2018-06-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=323377, encodeId=b2f43233e73d, content=创伤应激?, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18741984753, createdName=smartxiuxiu, createdTime=Mon Jun 11 22:41:16 CST 2018, time=2018-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=323354, encodeId=7b4432335412, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/6r91EF8BMOLCD55MqUYf0ibGeibzcwCxaSD5XqTv5sRrxxzV9TpHfN8fDaNYCt8Jay98QLKHyzBpkr1f4v2EIcDQ/132, createdBy=c24466863, createdName=liuchuan1982, createdTime=Mon Jun 11 21:01:38 CST 2018, time=2018-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=323341, encodeId=83b7323341c9, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=82311653708, createdName=医者仁心5538, createdTime=Mon Jun 11 20:26:03 CST 2018, time=2018-06-11, status=1, ipAttribution=)]
    2018-06-13 三生有幸9135

    学习一下谢谢

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1431238, encodeId=62db143123852, content=<a href='/topic/show?id=f9b9e9124a8' target=_blank style='color:#2F92EE;'>#综合征#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79124, encryptionId=f9b9e9124a8, topicName=综合征)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Wed Jun 13 11:12:00 CST 2018, time=2018-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=323741, encodeId=7856323e413a, content=学习一下谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzaiabIFicf63hKvVMjL6aJlx4yX4UcXmzX9DyibCRcicq0QtCRWMaQKh8MYjE1D3EKUBopgiaGWYuqbeR/0, createdBy=0c2b1999806, createdName=三生有幸9135, createdTime=Wed Jun 13 06:27:37 CST 2018, time=2018-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=323435, encodeId=274732343553, content=好文献学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b5a62240667, createdName=张新亮1853311252142e2fm, createdTime=Tue Jun 12 05:52:17 CST 2018, time=2018-06-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=323377, encodeId=b2f43233e73d, content=创伤应激?, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18741984753, createdName=smartxiuxiu, createdTime=Mon Jun 11 22:41:16 CST 2018, time=2018-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=323354, encodeId=7b4432335412, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/6r91EF8BMOLCD55MqUYf0ibGeibzcwCxaSD5XqTv5sRrxxzV9TpHfN8fDaNYCt8Jay98QLKHyzBpkr1f4v2EIcDQ/132, createdBy=c24466863, createdName=liuchuan1982, createdTime=Mon Jun 11 21:01:38 CST 2018, time=2018-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=323341, encodeId=83b7323341c9, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=82311653708, createdName=医者仁心5538, createdTime=Mon Jun 11 20:26:03 CST 2018, time=2018-06-11, status=1, ipAttribution=)]
    2018-06-12 张新亮1853311252142e2fm

    好文献学习了

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1431238, encodeId=62db143123852, content=<a href='/topic/show?id=f9b9e9124a8' target=_blank style='color:#2F92EE;'>#综合征#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79124, encryptionId=f9b9e9124a8, topicName=综合征)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Wed Jun 13 11:12:00 CST 2018, time=2018-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=323741, encodeId=7856323e413a, content=学习一下谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzaiabIFicf63hKvVMjL6aJlx4yX4UcXmzX9DyibCRcicq0QtCRWMaQKh8MYjE1D3EKUBopgiaGWYuqbeR/0, createdBy=0c2b1999806, createdName=三生有幸9135, createdTime=Wed Jun 13 06:27:37 CST 2018, time=2018-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=323435, encodeId=274732343553, content=好文献学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b5a62240667, createdName=张新亮1853311252142e2fm, createdTime=Tue Jun 12 05:52:17 CST 2018, time=2018-06-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=323377, encodeId=b2f43233e73d, content=创伤应激?, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18741984753, createdName=smartxiuxiu, createdTime=Mon Jun 11 22:41:16 CST 2018, time=2018-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=323354, encodeId=7b4432335412, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/6r91EF8BMOLCD55MqUYf0ibGeibzcwCxaSD5XqTv5sRrxxzV9TpHfN8fDaNYCt8Jay98QLKHyzBpkr1f4v2EIcDQ/132, createdBy=c24466863, createdName=liuchuan1982, createdTime=Mon Jun 11 21:01:38 CST 2018, time=2018-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=323341, encodeId=83b7323341c9, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=82311653708, createdName=医者仁心5538, createdTime=Mon Jun 11 20:26:03 CST 2018, time=2018-06-11, status=1, ipAttribution=)]
    2018-06-11 smartxiuxiu

    创伤应激?

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1431238, encodeId=62db143123852, content=<a href='/topic/show?id=f9b9e9124a8' target=_blank style='color:#2F92EE;'>#综合征#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79124, encryptionId=f9b9e9124a8, topicName=综合征)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Wed Jun 13 11:12:00 CST 2018, time=2018-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=323741, encodeId=7856323e413a, content=学习一下谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzaiabIFicf63hKvVMjL6aJlx4yX4UcXmzX9DyibCRcicq0QtCRWMaQKh8MYjE1D3EKUBopgiaGWYuqbeR/0, createdBy=0c2b1999806, createdName=三生有幸9135, createdTime=Wed Jun 13 06:27:37 CST 2018, time=2018-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=323435, encodeId=274732343553, content=好文献学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b5a62240667, createdName=张新亮1853311252142e2fm, createdTime=Tue Jun 12 05:52:17 CST 2018, time=2018-06-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=323377, encodeId=b2f43233e73d, content=创伤应激?, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18741984753, createdName=smartxiuxiu, createdTime=Mon Jun 11 22:41:16 CST 2018, time=2018-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=323354, encodeId=7b4432335412, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/6r91EF8BMOLCD55MqUYf0ibGeibzcwCxaSD5XqTv5sRrxxzV9TpHfN8fDaNYCt8Jay98QLKHyzBpkr1f4v2EIcDQ/132, createdBy=c24466863, createdName=liuchuan1982, createdTime=Mon Jun 11 21:01:38 CST 2018, time=2018-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=323341, encodeId=83b7323341c9, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=82311653708, createdName=医者仁心5538, createdTime=Mon Jun 11 20:26:03 CST 2018, time=2018-06-11, status=1, ipAttribution=)]
    2018-06-11 liuchuan1982

    学习了

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1431238, encodeId=62db143123852, content=<a href='/topic/show?id=f9b9e9124a8' target=_blank style='color:#2F92EE;'>#综合征#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79124, encryptionId=f9b9e9124a8, topicName=综合征)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Wed Jun 13 11:12:00 CST 2018, time=2018-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=323741, encodeId=7856323e413a, content=学习一下谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzaiabIFicf63hKvVMjL6aJlx4yX4UcXmzX9DyibCRcicq0QtCRWMaQKh8MYjE1D3EKUBopgiaGWYuqbeR/0, createdBy=0c2b1999806, createdName=三生有幸9135, createdTime=Wed Jun 13 06:27:37 CST 2018, time=2018-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=323435, encodeId=274732343553, content=好文献学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b5a62240667, createdName=张新亮1853311252142e2fm, createdTime=Tue Jun 12 05:52:17 CST 2018, time=2018-06-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=323377, encodeId=b2f43233e73d, content=创伤应激?, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18741984753, createdName=smartxiuxiu, createdTime=Mon Jun 11 22:41:16 CST 2018, time=2018-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=323354, encodeId=7b4432335412, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/6r91EF8BMOLCD55MqUYf0ibGeibzcwCxaSD5XqTv5sRrxxzV9TpHfN8fDaNYCt8Jay98QLKHyzBpkr1f4v2EIcDQ/132, createdBy=c24466863, createdName=liuchuan1982, createdTime=Mon Jun 11 21:01:38 CST 2018, time=2018-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=323341, encodeId=83b7323341c9, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=82311653708, createdName=医者仁心5538, createdTime=Mon Jun 11 20:26:03 CST 2018, time=2018-06-11, status=1, ipAttribution=)]
    2018-06-11 医者仁心5538

    学习了

    0

相关资讯

JAMA:PCI围术期患者需要应用负荷剂量他汀吗?从ARMYDA-ACS到ALPACS与ISCAP,再到SECURE-PCI

2018年ACC年会正在进行中。除了ODYSSEY OUTCOMES研究外,本届年会最受关注的另一个热点当属SECURE-PCI研究(Statins Evaluation in Coronary Procedures and Revascularization Trial)。

Lancet:双抗血小板治疗缩短至6个月导致PCI患者心肌梗死风险增加

研究认为对于急性冠脉综合征患者在支架植入后接受6个月的双抗血小板治疗与现行12个月的治疗指南相比,会导致患者心肌梗死和支架血栓风险增加。对于出血风险低的患者,至少12个月的双抗血小板治疗是必要的

EuroPCR 2018丨抗血小板界的“多面手”,你认识吗?

新研究丰富了替格瑞洛的多效性:替格瑞洛除抗血小板作用之外,还可带来额外获益。

2018 台湾专家共识:急性冠脉综合征抗血小板治疗不良反应管理

抗血小板治疗的急性冠脉综合征(ACS)治疗的重要组成部分,本文主要针对ACS患者接受抗血小板治疗的不良反应的管理提出指导建议,内容涉及上消化道出血的管理,淤血,血尿,鼻出血体积替卡格雷相关的呼吸困难的管理。

Circulation:普拉格雷与氯吡格雷用于经皮冠脉治疗后的急性冠脉综合征老年患者的效果对比

背景:与年轻患者相比,老年患者在急性冠脉综合征后缺血和出血性并发症的风险较高,而且氯吡格雷血小板反应性也更高。普拉格雷 5mg,与氯吡格雷相比,用于老年人时可发挥更多可预测的血小板抑制作用,提示可能可在不增加出血的情况下降低缺血风险。方法:研究人员进行一多中心的、随机的、开放性的、未知结点的临床试验,招募74岁以上的进行过经皮冠状动脉介入治疗的急性冠脉综合征患者,予以普拉格雷(5mg 1/日)或标

Radiology:冠脉周围脂肪沉积是急性斑块破裂及冠状动脉夹层的标识物

本研究旨在评价怀疑急性冠脉综合征(ACS)患者冠状动脉CTA上血管周围脂肪沉积的发生率及影响,并将结果发表在Radiology上。